LENZ THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
LENZ THERAPEUTICS, INC. (LENZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.89 per share for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $1.89, a 14.09% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $2.60, a 9.09% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.53, a 85.32% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $2.20, a 82.14% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.56, a 74.55% decline from fiscal 2021.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $6.13.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $1.89 10-Q · filed 2023-11-13 | $1.56 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $2.60 10-Q · filed 2023-08-14 | $1.54 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $1.53 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $1.56 10-K · filed 2024-02-27 | $5.21 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $2.20 10-Q · filed 2022-11-09 | $5.35 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $2.86 10-Q · filed 2022-08-11 | $5.70 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $10.42 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $6.13 10-K · filed 2022-03-21 | ||||
| 2021-09-30 | $12.32 10-Q · filed 2021-11-10 | $6.05 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $6.17 10-Q · filed 2021-08-12 | $5.44 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |